• ÆäÀ̽ººÏ °øÀ¯
  • Æ®À§ÅÍ °øÀ¯
  • ¹ÌÅõµ¥ÀÌ °øÀ¯
  • URLº¹»ç
  • ´õº¸±â
  • °ü½ÉÀÇ·áÁø µî·Ï

ÀÌÁöÇö

  • Áø·á°ú

    ¼Ò¾ÆÃ»¼Ò³â°ú

  • Àü¹®Áø·áºÐ¾ß

    ¼ÒÈ­±âÁúȯ (¼ö ¿ÀÀü-¼Ò¾Æ ³»½Ã°æ / ¸ñ ¿ÀÈÄ-¼ÒÈ­±â Ŭ¸®´Ð)

  • ´ã´çŬ¸®´Ð

ÀÌÁöÇö

ÀÌÁöÇö ±³¼öÀÇ Áø·á½Ã°£Ç¥ Áø·á¿¹¾à

Áø·á°ú/¼¾ÅÍ ¿ù È­ ¼ö ¸ñ ±Ý Åä Àü¹®Áø·á°ú¸ñ
¼Ò¾ÆÃ»¼Ò³â°ú
Á¾ÀÏ
-
¿ÀÀü
¿ÀÈÄ
- - ¼ÒÈ­±âÁúȯ (¼ö ¿ÀÀü-¼Ò¾Æ ³»½Ã°æ / ¸ñ ¿ÀÈÄ-¼ÒÈ­±â Ŭ¸®´Ð)

ÀÌÁöÇö ±³¼öÀÇ »ó¼¼Á¤º¸

ÇзÂ

more
  • 1994 .03  ~  2000 .02  :  °í·Á´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú Çлç
  • 2004 .09  ~  2006 .08  :  ¼º±Õ°ü´ëÇб³ Àǰú´ëÇпø ¼®»ç
  • 2007 .03  ~  2009 .02  :  ¼º±Õ°ü´ëÇб³ Àǰú´ëÇпø ¹Ú»ç

°æ·Â

more
  • 2000 .03  ~  2001 .02  :  °í´ëÀÇ·á¿ø ÀÎÅÏ ¼ö·á
  • 2002 .03  ~  2006 .02  :  »ï¼º¼­¿ïº´¿ø ¼Ò¾ÆÃ»¼Ò³â°ú Àü°øÀÇ ¼ö·á
  • 2006 .03  ~  2008 .08  :  »ï¼º¼­¿ïº´¿ø ¼Ò¾ÆÃ»¼Ò³â°ú ¼ÒÈ­±â¿µ¾ç ºÐ°ú ÀÓ»ó °­»ç
  • 2008 .09  ~  2014 .02  :  ÇѸ²´ëÇб³ °­³²¼º½Éº´¿ø ¼Ò¾ÆÃ»¼Ò³â°ú Á¶±³¼ö
  •  ~   :  ¼Ò¾Æ ¼ÒÈ­±â¿µ¾çºÐ°ú Àü¹®ÀÇ
  •  ~   :  ¼ÒÈ­±â³»½Ã°æ ¼¼ºÎ Àü¹®ÀÇ

ÇÐȸȰµ¿

more
  • 2002 .03  ~   :  ´ëÇÑ ¼Ò¾Æ°ú ÇÐȸ Á¤È¸¿ø
  • 2006 .03  ~   :  ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Á¤È¸¿ø
  • 2007 .03  ~   :  ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ Á¤È¸¿ø
  • 2013 .03  ~   :  ´ëÇÑ»óºÎÀ§Àå°ü Ç︮ÄÚ¹ÚÅÍÇÐȸ Á¤È¸¿ø
  • 2013 .03  ~   :  ´ëÇÑ»óºÎÀ§Àå°ü Ç︮ÄÚ¹ÚÅÍÇÐȸ ÇмúÀ§¿ø
  • 2014 .03  ~   :  ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ ÇмúÀ§¿ø

³í¹®

more
  • [±¹³»³í¹®] (Preventive effects of lactobacillus mixture on experimental E.coli urinary tract infection in infant Rats)
  • [±¹³»³í¹®] »êÀüÁøÂûÀ» Á¦´ë·Î ¹ÞÁö ¾ÊÀº »ê¸ð¿¡¼­ ž ¹Ì¼÷¾ÆÀÇ Á¶±â ¼±Ãµ ¸Åµ¶¿¡ ÀÇÇÑ »ç¸Á 1·Ê
  • [±¹¿Ü³í¹®] (A case of small bowel ulcer associsted with Helicobacter pylori)
  • [±¹³»³í¹®] (Clinical application of oral rehydration solution.)
  • [±¹¿Ü³í¹®] (Micronutrient Deficiency Syndrome: Zinc, Copper and Selenium)
  • [±¹¿Ü³í¹®] (Effects of proton pump inhibitors on pediatric infalmmatory esophagogastric polyps)
  • [±¹³»³í¹®] (The Long-term numeric and phenotypical changes of T regulatory cells in pediatric Crohn¡¯s disease with infliximab treatment)
  • [±¹³»³í¹®] ¼Ò¾ÆÃ»¼Ò³âÀÇ ¸¸¼º ¿°Áõ¼º ÀåÁú ȯ
  • [±¹³»³í¹®] (Changes in Glycogen and Glycosaminoglycan Levels in Hepatocytes of Iduronate-2-Sulfatase Knockout Mice before and after Recombinant Iduronate-2-Sulfatase Supplementation)
  • [±¹³»³í¹®] (Delaeyd reponse of amylin levels after an oral glucose challenge in chilren with Prader-Willi syndrome)
  • [±¹³»³í¹®] (Gaps between infant diarrheal disease and frequent loose stool)
  • [±¹³»³í¹®] ¼Ò¾Æ »óÇà ´ëÀå °Ô½Ç¿° õ°ø1·Ê
  • [±¹¿Ü³í¹®] (Efficacy of early treatment with infliximab in pediatric Crohn's disease)
  • [±¹³»³í¹®] (A single center experience of self-bougienage on stricture recurrence after sufgery for corrosive esophageal strictures in children)
  • [±¹³»³í¹®] (Helicobacter pylori urease activity is influenced by ferric uptake regulator)
  • [±¹³»³í¹®] (Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea)
  • [±¹¿Ü³í¹®] (Disseminated Kikuchi-Fujimoto Disease mimicking Malignant Lymphoma on Positron Emission Tomography in a Child)
  • [±¹¿Ü³í¹®] (The expression of iron-repressible outer membrane proteins in Helicobacter pylori and its association with iron deficiency anemia)
  • [±¹¿Ü³í¹®] ¿°Áõ¼º °ÅÁþ Á¾¾çÀ¸·Î ¿ÀÀÎµÈ °£ ³» ¹ß»ýÇÑ ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • [±¹³»³í¹®] (Diagnosis of inflammatory bowel disease in children)
  • [±¹³»³í¹®] Infliximab:ºÒÀÀ¼º Å©·Ðº´ Ä¡·á¹ýÀ¸·Î¼­ÀÇ À¯¿ë¼º°ú Top-down °üÇØ À¯µµ ¿ä¹ýÀ¸·Î¼­ÀÇ °¡´É¼º
  • [±¹³»³í¹®] °Å´ë °£ Á¾±«¿Í ½É¹æ Áß°Ý °á¼ÕÀ» µ¿¹ÝÇÑ Abernethy ±âÇü 2¿¹
  • [±¹³»³í¹®] ¼±Ãµ¼º °£ ¼¶À¯ÁõÀ» µ¿¹ÝÇÑ Kanuki ÁõÈıº 1¿¹
  • [±¹¿Ü³í¹®] (Allergic proctitis and abominal distention mimicking Hirschsprung's disease in infants)
  • [±¹¿Ü³í¹®] (Ghrelin levels in gastric mucosa before and after eradication of H. pylori)
  • [±¹³»³í¹®] ¼Ò¾Æ¿¡¼­ À§Àå°ü À̹°ÀÇ ÀÚ¿¬ ¹èÃâ¿¡ ´ëÇÑ °æÇèÀû °íÂû
  • [±¹³»³í¹®] ³ú¼ö¸ð¼¼Æ÷Á¾ ¹× °¡Á·¼º ¼±Á¾¼º ¿ëÁ¾ÁõÀ¸·Î ¹ßÇöÇÑ Turcot ÁõÈıº 1¿¹
  • [±¹¿Ü³í¹®] (The development of eosinophilic colitis after liver transplantation in children)
  • [±¹³»³í¹®] ¼Ò¾Æ¿¡¼­ ´Á¸· »ïÃâ¾×À» µ¿¹ÝÇÑ ¿Ü»ó¼º ÃéÀå Àý´Ü ¹× ÃéÀå ÁÖ°ü ¼Õ»ó 1¿¹
  • [±¹³»³í¹®] ÀÚ°¡¸é¿ª°£¿°°ú ¿ø¹ß¼º °æÈ­´ã°ü¿°À» °¡Áø Áߺ¹ÁõÈıº ¼Ò¾Æ ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ÇüÁú¼¼È£¼º °ñ¼ö¿° 1¿¹
  • [±¹³»³í¹®] ¼Ò¾Æ °£À̽ÄÈÄÀÇ È£»ê±¸¼º À§Àå¿° ¹ß»ý ¹× À§Çè ÀÎÀÚ ºÐ¼®
  • [±¹³»³í¹®] 1996³â-2004³â ¼­¿ïÁö¿ª ÇÑ ÀÇ·á±â°ü¿¡¼­ÀÇ ÀÏÂ÷¼º ¸é¿ª°áÇÌÁõ ȯÀÚ¿¡ °üÇÑ ÀÓ»ó ºÐ¼®
  • [±¹³»³í¹®] (Clinical and Laboratory Features of Korean Mucopolysaccharidoses (MPSs))
  • [±¹³»³í¹®] ÁßÁõ °íºô¸®·çºóÇ÷Áõ (Ç÷û ºô¸®·çºó>25 mg/dL)ÀÇ ¹ßº´¿øÀΰú Ä¡·á ¹× ¿¹ÈÄ
  • [±¹³»³í¹®] ¼Ò¾Æ¿¡¼­ ½ÃÇàÇÑ Ä¡·áÀû Ç÷À屳ȯ¼ú 9·ÊÀÇ ÀÓ»óÀû °íÂû

ÃÖÁ¾¼öÁ¤ÀÏ : 2021.01.12